David J A Goldsmith

List of Publications by Year
in descending order

207 papers	9,010 citations	30070 54 h-index	49909 87 g-index
293 all docs	293 docs citations	293 times ranked	9980 citing authors

#	Article	IF	Citations
1	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology Dialysis Transplantation, 2013, 28, 1346-1359.	0.7	628
2	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet, The, 2014, 383, 1831-1843.	13.7	341
3	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 42-61.	5.2	260
4	Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. International Urology and Nephrology, 2014, 46, 1619-1625.	1.4	196
5	Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrology Dialysis Transplantation, 2009, 24, 1506-1523.	0.7	189
6	Immunogenicity of biopharmaceuticals. Nephrology Dialysis Transplantation, 2006, 21, v9-v12.	0.7	164
7	Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney International, 2004, 65, 1790-1794.	5.2	149
8	Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrology Dialysis Transplantation, 2004, 19, 2307-2312.	0.7	147
9	The double challenge of resistant hypertension and chronic kidney disease. Lancet, The, 2015, 386, 1588-1598.	13.7	147
10	Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nature Reviews Nephrology, 2012, 8, 362-369.	9.6	143
11	Vascular calcification: A stiff challenge for the nephrologist. Kidney International, 2004, 66, 1315-1333.	5.2	140
12	Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrology Dialysis Transplantation, 2015, 30, 1542-1551.	0.7	140
13	Arterial Stiffness in Renal Patients: An Update. American Journal of Kidney Diseases, 2005, 45, 965-977.	1.9	138
14	Assessment and Management of Hypertension in Transplant Patients. Journal of the American Society of Nephrology: JASN, 2015, 26, 1248-1260.	6.1	138
15	Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney International, 2013, 84, 998-1008.	5.2	136
16	Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients. American Journal of Kidney Diseases, 2004, 43, 313-319.	1.9	132
17	Active Vitamin D Treatment for Reduction of Residual Proteinuria. Journal of the American Society of Nephrology: JASN, 2013, 24, 1863-1871.	6.1	126
18	Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes and Endocrinology,the, 2014, 2, 427-436.	11.4	125

#	Article	IF	Citations
19	Pulmonary Hypertension in CKD. American Journal of Kidney Diseases, 2013, 61, 612-622.	1.9	119
20	Bone Alkaline Phosphatase in CKDâ€“Mineral Bone Disorder. American Journal of Kidney Diseases, 2013, 62, 810-822.	1.9	111
21	Posttransplantation Anemia in Adult Renal Allograft Recipients: Prevalence and Predictors. Transplantation, 2006, 81, 1112-1118.	1.0	104
22	Thrombotic Micro-Angiopathy with Sirolimus-Based Immunosuppression: Potentiation of Calcineurin-Inhibitor-Induced Endothelial Damage?. American Journal of Transplantation, 2003, 3, 324-327.	4.7	103
23	Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?. Nephrology Dialysis Transplantation, 2014, 29, 1815-1820.	0.7	103
24	Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes and Endocrinology,the, 2018, 6, 319-331.	11.4	102
25	Increased arterial stiffness in children on haemodialysis. Nephrology Dialysis Transplantation, 2006, 21, 729-735.	0.7	101
26	Sodium Thiosulfate: New Hope for the Treatment of Calciphylaxis. Seminars in Dialysis, 2010, 23, 258-262.	1.3	101
27	Adynamic Bone Disease: From Bone to Vessels in Chronic Kidney Disease. Seminars in Nephrology, 2014, 34, 626-640.	1.6	101
28	Serum Sclerostin and Adverse Outcomes in Nondialyzed Chronic Kidney Disease Patients. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1854-E1861.	3.6	99
29	Anticoagulation in Concomitant Chronic Kidney Disease and AtrialÂFibrillation. Journal of the American College of Cardiology, 2019, 74, 2204-2215.	2.8	94
30	Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney International, 2012, 81, 727-732.	5.2	92
31	Impact of Vitamin D Supplementation on Arterial Vasomotion, Stiffness and Endothelial Biomarkers in Chronic Kidney Disease Patients. PLoS ONE, 2014, 9, e91363.	2.5	91
32	Infective endocarditis in dialysis patients: New challenges and old. Kidney International, 2003, 64, 720-727.	5.2	89
33	PTHâ€”A Particularly Tricky Hormone. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 299-312.	4.5	89
34	Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrology Dialysis Transplantation, 2012, 27, 3270-3278.	0.7	87
35	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrology Dialysis Transplantation, 2010, 25, 3823-3831.	0.7	85
36	Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. Nephrology Dialysis Transplantation, 2014, 29, 232-239.	0.7	81

#	Article	IF	Citations
37	Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: A prospective, crossover study. Nephrology, 2012, 17, 710-717.	1.6	80
38	Aerobic or Resistance Training and Pulse Wave Velocity in Kidney Transplant Recipients: A 12-Week Pilot Randomized Controlled Trial (the Exercise in Renal Transplant [ExeRT] Trial). American Journal of Kidney Diseases, 2015, 66, 689-698.	1.9	80
39	COSMOS: the dialysis scenario of CKDâ€“MBD in Europe. Nephrology Dialysis Transplantation, 2013, 28, 1922-1935.	0.7	79
40	Focus on renal congestion in heart failure. CKJ: Clinical Kidney Journal, 2016, 9, 39-47.	2.9	77
41	Assessing glycemic control in patients with diabetes and end-stage renal failure. American Journal of Kidney Diseases, 2003, 41, 523-531.	1.9	75
42	Phosphate â€“ The Silent Stealthy Cardiorenal Culprit in All Stages of Chronic Kidney Disease. Blood Purification, 2009, 27, 220-230.	1.8	73
43	Sirolimus-Induced Pneumonitis: Three Cases and a Review of the Literature. American Journal of Transplantation, 2004, 4, 137-139.	4.7	72
44	Cardiac calcification in renal patients: what we do and don't know. American Journal of Kidney Diseases, 2004, 43, 234-243.	1.9	72
45	Anemia After Renal Transplantation. American Journal of Kidney Diseases, 2006, 48, 519-536.	1.9	72
46	Allergic reactions to the polymeric glucose-based peritoneal dialysis fluid icodextrin in patients with renal failure. Lancet, The, 2000, 355, 897.	13.7	69
47	Risk Factors for Severe Renal Disease in Bardetâ€“Biedl Syndrome. Journal of the American Society of Nephrology: JASN, 2017, 28, 963-970.	6.1	69
48	Four months into the COVID-19 pandemic, Swedenâ€™s prized herd immunity is nowhere in sight. Journal of the Royal Society of Medicine, 2020, 113, 292-298.	2.0	69
49	Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. BMJ: British Medical Journal, 2018, 360, k342.	2.3	68
50	Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. International Urology and Nephrology, 2008, 40, 443-451.	1.4	67
51	Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrology, 2016, 17, 97.	1.8	66
52	Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrology Dialysis Transplantation, 2008, 23, 3731-3737.	0.7	62
53	Renal Anemia of Inflammation: The Name Is Self-Explanatory. Blood Purification, 2011, 32, 220-225.	1.8	62
54	Arterial wave reflections and mortality in haemodialysis patientsâ€”only relevant in elderly, cardiovascularly compromised?. Nephrology Dialysis Transplantation, 2006, 21, 2859-2866.	0.7	60

#	Article	IF	Citations
55	Vascular Calcification and Bone Mineral Density in Recurrent Kidney Stone Formers. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 278-285.	4.5	60
56	The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. Kidney International Supplements, 2011, 1, 6-9.	14.2	57
57	Serum Vitamin D Levels are Independently Associated with Severity of Coronary Artery Disease. Journal of Investigative Medicine, 2012, 60, 869-873.	1.6	54
58	Pro: Cardiovascular calcifications are clinically relevant. Nephrology Dialysis Transplantation, 2015, 30, 345-351.	0.7	53
59	Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?. Nephrology Dialysis Transplantation, 2016, 31, 1211-1219.	0.7	52
60	Insights from ambulatory blood pressure monitoring: diagnosis of hypertension and diurnal blood pressure in renal transplant recipients. Transplantation, 2004, 77, 849-853.	1.0	50
61	Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?. Nephrology Dialysis Transplantation, 2014, 29, 1275-1284.	0.7	50
62	Mammalian Target of Rapamycin (mTOR) Inhibitors. Drug Safety, 2011, 34, 97-115.	3.2	49
63	Influence of Body Mass Index on the Association of Weight Changes with Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1725-1733.	4.5	49
64	Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrology, 2013, 14, 24.	1.8	48
65	Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD) â€“ A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0187025.	2.5	46
66	Anaemia, microcytosis and sirolimus--is iron the missing link?. Nephrology Dialysis Transplantation, 2010, 25, 1667-1675.	0.7	44
67	Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nature Reviews Nephrology, 2012, 8, 141-150.	9.6	44
68	News on Biomarkers in CKDâ€MBD. Seminars in Nephrology, 2014, 34, 598-611.	1.6	44
69	Bullous dermatoses in end-stage renal failure: Porphyria or pseudoporphyria?. American Journal of Kidney Diseases, 1999, 34, 155-160.	1.9	41
70	Effect of reninâ€“angiotensinâ€“aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2018, 33, 12-22.	0.7	39
71	Differential Effect of sirolimus vs prednisolone in the treatment of sclerosing encapsulating peritonitis. Nephrology Dialysis Transplantation, 2002, 17, 2278-2280.	0.7	38
72	Cardiorenal Syndrome and the Role of the Bone-Mineral AxisÂandÂAnemia. American Journal of Kidney Diseases, 2015, 66, 196-205.	1.9	38

#	Article	IF	Citations
73	Pro: Should we correct vitamin D deficiency/insufficiency in chronic kidney disease patients with inactive forms of vitamin D or just treat them with active vitamin D forms?: TableÂ1.. Nephrology Dialysis Transplantation, 2016, 31, 698-705.	0.7	35
74	New options for the anemia of chronic kidney disease. Kidney International Supplements, 2017, 7, 157-163.	14.2	35
75	Systematic Review of the Evidence Underlying the Association Between Mineral Metabolism Disturbances and Risk of Fracture and Need for Parathyroidectomy in CKD. American Journal of Kidney Diseases, 2009, 53, 1002-1013.	1.9	34
76	Management of atrial fibrillation in chronic kidney disease: Double trouble. American Heart Journal, 2013, 166, 230-239.	2.7	34
77	Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Nephrology Dialysis Transplantation, 2014, 29, 899-905.	0.7	34
78	Phosphodiesterase type 5 inhibitors and kidney disease. International Urology and Nephrology, 2015, 47, 1521-1528.	1.4	34
79	Novel Faces of Fibroblast Growth Factor 23 (FGF23): Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury. Calcified Tissue International, 2017, 100, 217-228.	3.1	34
80	A Review of Safety, Efficacy, and Utilization of Erythropoietin, Darbepoetin, and Peginesatide for Patients with Cancer or Chronic Kidney Disease: A Report from the Southern Network on Adverse Reactions (SONAR). Seminars in Thrombosis and Hemostasis, 2012, 38, 783-796.	2.7	32
81	Relapsing culture-negative peritonitis in peritoneal dialysis patients exposed to icodextrin solution. American Journal of Kidney Diseases, 2002, 40, 1030-1035.	1.9	31
82	Ambulatory blood pressure monitoring in renal transplantation: should ABPM be routinely performed in renal transplant patients?. Transplantation, 2003, 76, 1640-1642.	1.0	31
83	Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrology Dialysis Transplantation, 2012, 27, 1942-1949.	0.7	31
84	Long-term pulse wave velocity outcomes with aerobic and resistance training in kidney transplant recipients â€“ A pilot randomised controlled trial. PLoS ONE, 2017, 12, e0171063.	2.5	31
85	Dynamics of the Circadian Blood Pressure Profiles after Renal Transplantation. Transplantation, 2005, 80, 1168-1173.	1.0	30
86	Septic arthritis due to extended spectrum beta lactamase producing Klebsiella pneumoniae. Joint Bone Spine, 2007, 74, 275-278.	1.6	30
87	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. CKJ: Clinical Kidney Journal, 2019, 12, 269-280.	2.9	29
88	An economic evaluation of sevelamer in patients new to dialysis. Current Medical Research and Opinion, 2008, 24, 601-608.	1.9	28
89	18F-fluoride Positron Emission Tomography Measurements of Regional Bone Formation in Hemodialysis Patients with Suspected Adynamic Bone Disease. Calcified Tissue International, 2013, 93, 436-447.	3.1	28
90	Low-Dose Mycophenolate Mofetil is an Effective and Safe Treatment to Permit Phased Reduction in Calcineurin Inhibitors in Chronic Allograft Nephropathy. Transplantation, 2005, 79, 304-309.	1.0	27

#	Article	IF	Citations
91	Guidelines for Submitting Adverse Event Reports for Publication. Therapie, 2009, 64, 289-294.	1.0	27
92	Erythropoiesis-Stimulating Agents (ESA) for Preventing the Progression of Chronic Kidney Disease: A Meta-Analysis of 19 Studies. American Journal of Nephrology, 2014, 40, 263-279.	3.1	27
93	Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clinical Transplantation, 2004, 18, 201-204.	1.6	26
94	Vitamin D analogues to target residual proteinuria: potential impact on cardiorenal outcomes. Nephrology Dialysis Transplantation, 2015, 30, 1988-1994.	0.7	26
95	Post-transplantation anaemia in adult and paediatric renal allograft recipientsâ€"Guy's Hospital experience. Nephrology Dialysis Transplantation, 2006, 21, 1974-1980.	0.7	25
96	2009. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 929-935.	4.5	25
97	Brain-kidney cross-talk: Definition and emerging evidence. European Journal of Internal Medicine, 2016, 36, 7-12.	2.2	25
98	From Finland to Fatland: Beneficial Effects of Statins for Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, 2161-2168.	6.1	24
99	Cost-Effectiveness of Lanthanum Carbonate versus Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease: A US Payer Perspective. Value in Health, 2011, 14, 1002-1009.	0.3	24
100	Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?. Clinical Drug Investigation, 2018, 38, 481-490.	2.2	24
101	Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clinical Science, 2004, 107, 63-68.	4.3	23
102	What we CAN do about chronic allograft nephropathy: Role of immunosuppressive modulations. Kidney International, 2005, 68, 2429-2443.	5.2	23
103	Summary of the 5th Edition of the Renal Association Clinical Practice Guidelines (2009â€"2012). Nephron Clinical Practice, 2011, 118, c27-c70.	2.3	23
104	Regression of vascular calcification in chronic kidney disease â€" feasible or fantasy? A review of the clinical evidence. British Journal of Clinical Pharmacology, 2013, 76, 560-572.	2.4	23
105	Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrology Dialysis Transplantation, 2015, 30, 698-700.	0.7	23
106	Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. Nephrology Dialysis Transplantation, 2019, 34, 673-681.	0.7	23
107	Historic psychedelic drug trials and the treatment of anxiety disorders. Depression and Anxiety, 2020, 37, 1261-1279.	4.1	23
108	Statins in chronic kidney disease and kidney transplantation. Pharmacological Research, 2014, 88, 62-73.	7.1	22

#	Article	IF	Citations
109	Intravenous iron therapy in renal failure: friend and foe?. Journal of Nephrology, 2004, 17, 487-95.	2.0	21
110	Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). Journal of Nephrology, 2008, 21, 290-8.	2.0	21
111	The metabolic syndrome following kidney transplantation. Kidney International, 2010, 78, S8-S14.	5.2	20
112	Vitamin D and osteoporosis in chronic kidney disease. Journal of Nephrology, 2017, 30, 671-675.	2.0	20
113	Ambulatory blood pressure monitoring: an essential tool for blood pressure assessment in uraemic patients. Nephrology Dialysis Transplantation, 2002, 17, 1737-1741.	0.7	19
114	Stimulating Erythropoiesis: Future Perspectives. Kidney and Blood Pressure Research, 2008, 31, 234-246.	2.0	19
115	Mineral metabolism and vitamin D in chronic kidney diseaseâ€"more questions than answers. Nature Reviews Nephrology, 2011, 7, 341-346.	9.6	18
116	Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease. Pediatric Nephrology, 2015, 30, 1843-1852.	1.7	18
117	Magnesium-based interventions for normal kidney function and chronic kidney disease. Magnesium Research, 2016, 29, 126-140.	0.5	18
118	Determinants of vitamin <scp>D</scp> status in longâ€term renal transplant patients. Clinical Transplantation, 2012, 26, E617-23.	1.6	17
119	How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure?. Nephrology Dialysis Transplantation, 2002, 17, 965-969.	0.7	16
120	Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA). Nephrology Dialysis Transplantation, 2010, 25, 1734-1737.	0.7	16
121	Comparison of estimated GFR and measured GFR in prospective living kidney donors. International Urology and Nephrology, 2015, 47, 201-208.	1.4	16
122	Bleeding in advanced CKD patients on antithrombotic medication â€“ A critical appraisal. Pharmacological Research, 2018, 129, 535-543.	7.1	16
123	Dyslipidemia, statins, and CKD patientsâ€™ outcomes â€“ review of the evidence in the post-sharp era. Journal of Nephrology, 2012, 25, 460-472.	2.0	16
124	Rectus sheath haematomata in patients with renal disease. Nephrology Dialysis Transplantation, 2002, 17, 1832-1835.	0.7	15
125	Systolic Blood Pressure Diurnal Variation is Not a Predictor of Renal Target Organ Damage in Kidney Transplant Recipients. American Journal of Transplantation, 2004, 4, 244-247.	4.7	15
126	Through the looking glass: the protein science of biosimilars. Clinical and Experimental Nephrology, 2007, 11, 191-195.	1.6	15

#	Article	IF	Citations
127	The use of echocardiography in observational clinical trials: the EURECA-m registry. Nephrology Dialysis Transplantation, 2013, 28, 19-23.	0.7	15
128	Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2019, 34, 2051-2057.	0.7	15
129	Glomerular filtration rate in prospective living kidney donors. International Urology and Nephrology, 2013, 45, 1445-1452.	1.4	14
130	Vitamin K status in chronic kidney disease: a report of a study and a mini-review. International Urology and Nephrology, 2013, 45, 1339-1344.	1.4	14
131	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2017, 32, 1967-1976.	0.7	14
132	Relationships between blood pressure variability and left ventricular parameters in haemodialysis and renal transplant patients. Nephrology, 1998, 4, 87-93.	1.6	12
133	Impact of vitamin D on cardiac structure and function in chronic kidney disease patients with hypovitaminosis D: a randomized controlled trial and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 302-311.	3.0	12
134	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Vascular Calcificationâ€"A New Window on the Cardiovascular System: Role of Agents Used to Manipulate Skeletal Integrity. Seminars in Dialysis, 2007, 20, 158-169.	1.3	11
135	Clinical imaging of vascular disease in chronic kidney disease. International Urology and Nephrology, 2016, 48, 827-837.	1.4	11
136	Nomenclature in nephrology: preserving â€˜renalâ€™ and â€˜nephro' in the glossary of kidney health and disease. Journal of Nephrology, 2021, 34, 639-648.	2.0	11
137	Ambulatory blood pressure measurement in the renal patient. Current Hypertension Reports, 2002, 4, 369-376.	3.5	10
138	Autonomic neuropathy with B-cell lymphoma. Journal of the Royal Society of Medicine, 2000, 93, 377-378.	2.0	9
139	Statins and kidney disease. Current Opinion in Cardiology, 2012, 27, 429-440.	1.8	9
140	Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease. International Urology and Nephrology, 2012, 44, 1169-1175.	1.4	9
141	Long-term safety and efficacy of reninâ€"angiotensin blockade in atherosclerotic renal artery stenosis. International Urology and Nephrology, 2012, 44, 1451-1459.	1.4	9
142	A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study. Internal and Emergency Medicine, 2013, 8, 389-399.	2.0	9
143	Routine Bioimpedance-Derived Volume Assessment for All Hypertensives: A New Paradigm. American Journal of Nephrology, 2014, 40, 434-440.	3.1	9
144	Current dilemmas in inhibiting the reninâ€"angiotensin system: do not forget real life. International Urology and Nephrology, 2007, 39, 571-576.	1.4	8

#	Article	IF	Citations
145	Negative Outcome Studies in End-Stage Renal Disease. Blood Purification, 2008, 26, 63-66.	1.8	8
146	Analysis of Blood Pressure Variability Derived from Ambulatory Blood Pressure Monitoring in 92 Uraemic Patients. Contributions To Nephrology, 1996, 119, 157-160.	1.1	7
147	Anaemia after Renal Transplantation â€“ Role of Immunosuppressive Drugs and a Pathophysiological Appraisal. Nephron Clinical Practice, 2006, 104, c69-c74.	2.3	7
148	Extraordinary popular delusions and the madness of crowds: puncturing the epoetin bubble--lessons for the future. Nephrology Dialysis Transplantation, 2011, 26, 24-28.	0.7	7
149	Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression. Current Vascular Pharmacology, 2014, 12, 155-167.	1.7	7
150	Long-term treatment with biosimilar epoetin-Î± (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study. Clinical Nephrology, 2018, 89, 1-9.	0.7	7
151	Serious interaction between tacrolimus FK506 and chloramphenicol in a kidney-pancreas transplant recipient. Transplant International, 2003, 16, 441-443.	1.6	6
152	Oral phosphate binders in CKD Ã¢Â€Â“ is calcium the (only) answer?. Clinical Nephrology, 2014, 81, 389-395.	0.7	6
153	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 357-357.	0.7	6
154	Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study. BMC Nephrology, 2019, 20, 81.	1.8	6
155	Recent insights from studies using ambulatory blood pressure monitoring in patients with renal disease. Current Opinion in Nephrology and Hypertension, 2003, 12, 645-648.	2.0	5
156	Biosimilars. Pharmaceutical Medicine, 2007, 21, 199-206.	0.4	5
157	Calcium and the saga of the binders: accumulating controversy, or building consensus?. International Urology and Nephrology, 2008, 40, 1009-1014.	1.4	5
158	Clinical Features and Manifestations of CKD-MBD. Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 142-148.	0.8	5
159	Rebuttal. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 319-320.	4.5	5
160	<scp>SPRINT</scp>: The Study Nephrologists Might Take With a Grain of Salt. Journal of Clinical Hypertension, 2016, 18, 1185-1188.	2.0	5
161	Parathyroid hormone measurements, guidelines statements and clinical treatments: a real-world cautionary tale. Annals of Clinical Biochemistry, 2012, 49, 4-6.	1.6	4
162	Case report: making the CONN-ection: two cases of persistent hypertension and hypokalaemia following renal transplantation. International Urology and Nephrology, 2012, 44, 1577-1580.	1.4	4

#	Article	IF	Citations
163	From Profusion to Confusion: The Saga of Managing Hypertension in Chronic Kidney Disease!. Journal of Clinical Hypertension, 2015, 17, 421-427.	2.0	4
164	Impact of seasonality on the dynamics of native Vitamin D repletion in long-term renal transplant patients. CKJ: Clinical Kidney Journal, 2017, 10, sfw136.	2.9	4
165	Adaptation and Implementation of the "Kidney Disease: Improving Global Outcomes (KDIGO)" Guidelines for Evaluation and Management of Mineral and Bone Disorders in Chronic Kidney Disease for Practice in the Middle East Countries. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2014, 25, 133.	0.3	4
166	Persistent Post-Transplant Autonomous Hyperparathyroidism despite 23 Years of Excellent Renal Allograft Function. Nephron, 2001, 89, 105-107.	1.8	3
167	Ambulatory Blood Pressure Measurements in Chronic Kidney Disease: Ready to (Rock and) Roll?. Archives of Internal Medicine, 2011, 171, 1098-9.	3.8	3
168	The management of end-stage heart failure and reducing the risk of cardiorenal syndrome. Clinical Medicine, 2013, 13, 610-613.	1.9	3
169	Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study). International Urology and Nephrology, 2015, 47, 837-845.	1.4	3
170	Sudden death of a patient with polycystic kidneys due to acute inferior vena cava thrombosis. Scottish Medical Journal, 2016, 61, 171-173.	1.3	3
171	HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience. Drug Design, Development and Therapy, 2018, Volume 12, 9-14.	4.3	3
172	Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients. Nefrologia, 2018, 38, 520-527.	0.4	3
173	Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients. Nefrologia, 2018, 38, 520-527.	0.4	3
174	Organ calcification in renal hyperparathyroidism. Journal of the Royal Society of Medicine, 1998, 91, 611-611.	2.0	2
175	Life-threatening rectal bleeding due to cytomegalovirus colitis in a haemodialysis patient. CKJ: Clinical Kidney Journal, 2009, 2, 239-241.	2.9	2
176	The battle against obesity: lessons from tobacco. Lancet, The, 2011, 378, 2069.	13.7	2
177	Medical and Surgical Management (Including Diet). Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 174-183.	0.8	2
178	The prevalence of electrocardiographic early repolarization in an adult cohort with chronic kidney disease and its impact upon all-cause mortality and progression to dialysis. Frontiers in Physiology, 2013, 4, 127.	2.8	2
179	Repeated renal infarction in native and transplanted kidneys due to left ventricular thrombus formation caused by antiphospholipid antibody syndrome. International Medical Case Reports Journal, 2013, 6, 7.	0.8	2
180	Biosimilars: uncharted territory. Journal of Nephrology, 2007, 20, 265-7.	2.0	2

#	Article	IF	Citations
181	Blood pressure variability measurements. Nephrology Dialysis Transplantation, 2000, 15, 131-132.	0.7	1
182	Spontaneous Abdominal Hemorrhage with AA-amyloidosis and Vasculitis in a Patient with Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2001, 7, 86-90.	0.9	1
183	Spontaneous and protracted partial remission of microscopic polyangiitis. American Journal of Kidney Diseases, 2002, 39, 1113-1117.	1.9	1
184	WaldenstrÃ¶m's macroglobulinaemia presenting as isolated epistaxis: a common complaint but a rare cause. International Journal of Clinical Practice, 2004, 58, 81-82.	1.7	1
185	Commentary. Nephrology Dialysis Transplantation, 2006, 21, v1-v3.	0.7	1
186	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Introduction: The Binders Wars 1987-2007: Double Decades of Denial, Doubt, Delay. Seminars in Dialysis, 2007, 20, 101-102.	1.3	1
187	Nocturnal Hypertension in Dialysis Patients. Seminars in Dialysis, 1998, 11, 261-263.	1.3	1
188	Promoting scientific collaboration and education in cardiovascular-renal medicine: EURECAM: An ERA-EDTA-based working group. CKJ: Clinical Kidney Journal, 2009, 2, 522-525.	2.9	1
189	Detection of bowel cancer in kidney transplant recipients. BMJ, The, 2012, 345, e5081-e5081.	6.0	1
190	Low Sodium Diet, Vitamin D, or Both for RAASi-Resistant, Residual, Proteinuria in CKD? The ViRTUE Trial Points the Way Forward but Is Not the Last Word. Journal of the American Society of Nephrology: JASN, 2017, 28, 1016-1019.	6.1	1
191	Effect of Vitamin D on Endothelial Function and Blood Pressure. , 2015, , 99-105.		1
192	Infections in Hemodialysis. , 0, , 441-451.		1
193	High blood pressure and the kidney. Kidney International, 2000, 58, 1358.	5.2	0
194	What's in a blister? A diagnostic twister. Nephrology Dialysis Transplantation, 2004, 19, 1321-1322.	0.7	0
195	A new approach to authorship: Institutions must decide. Journal of the Royal Society of Medicine, 2012, 105, 501-501.	2.0	0
196	Maternal vitamin D status during pregnancy and bone-mineral content in offspring. Lancet, The, 2013, 382, 766-767.	13.7	0
197	The Janus faces of ESAs: caveat Chimaera!. International Urology and Nephrology, 2013, 45, 761-767.	1.4	0
198	Reply to Jolobe. American Heart Journal, 2014, 167, e3.	2.7	0

#	Article	IF	Citations
199	SP399BENEFICIAL IMMUNOMODULATORY EFFECT OF CHOLECALCIFEROL REPLETION IN CKD PATIENTS : DOWN-REGULATION OF CELL SURFACE HLA-DR EXPRESSION MAY EXPLAIN REDUCTION IN INFLAMMATION. Nephrology Dialysis Transplantation, 2015, 30, iii511-iii511.	0.7	0
200	FO031THE EFFECT OF AEROBIC OR RESISTANCE TRAINING ON VASCULAR HEALTH, CARDIO-RESPIRATORY FITNESS, QUALITY OF LIFE, PHYSICAL FUNCTION, AND INFLAMMATORY BIOMARKERS IN KIDNEY TRANSPLANT RECIPIENTS: A PILOT RANDOMISED CONTROLLED TRIAL - THE EXERT STUDY. Nephrology Dialysis Transplantation, 2015, 30, iii16-iii16.	0.7	0
201	Opponent's comments. Nephrology Dialysis Transplantation, 2016, 31, 713-713.	0.7	0
202	Clinical outcomes with iron-based phosphate binders for CKD patients. Journal of Kidney Care, 2017, 2, 92-99.	0.1	0
203	SP363DESIGN OF A MULTICENTER, NON-INTERVENTIONAL, POST-AUTHORIZATION SAFETY STUDY OF ANEMIC CKD PATIENTS RECEIVING BIOSIMILAR EPOETIN ALFA. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
204	Dyslipidemia and Chronic Kidney Disease. , 2020, , 1093-1101.		0
205	CVD in CKD: Focus on the Dyslipidemia Problem. , 2014, , 67-91.		0
206	Control of Secondary Hyperparathyroidism (SPHT) by Older and Newer Vitamin D Compounds. , 2020, , 151-154.		0
207	Early recognition the key to CKD. Practitioner, 2007, 251, 35-6, 38, 41-2.	0.3	0